Study Uses Calypso 4D Localization System
Tulsa, Okla., Dec. 27, 2011 - Cancer Treatment Centers of America (CTCA) in Tulsa, Okla., announces that after obtaining Institutional Review Board approval and informed consent,
the hospital has enrolled the first U.S. patient in a clinical trial to evaluate a new transponder for patients undergoing radiation treatment for lung cancer using the Calypso 4D Localization
System (currently FDA-approved for prostate cancer).
CTCA currently uses standard transponders from the Calypso System during radiation treatment of prostate cancer patients to improve the accuracy of treatment delivery. CTCA is
investigating the new transponder for use in the lung.
“This study could help advance the treatment of lung masses, whether it may be a lung cancer or metastases,” said Dr. Daniel Nader, national clinical director, pulmonary/critical care
and interventional pulmonologist at CTCA, who is the principal investigator of the study.
Sub-investigators are CTCA Radiation Oncologists Drs. Michael Payne, Oneita Taylor, James Flynn and William Goad.
The clinical trial is underway worldwide, with sites in the U.S. at Washington University in St. Louis and CTCA in Tulsa. In this study, specially designed transponders are placed in the
lung using fluoroscopy and SuperDimension Navigational Bronchoscopy (at Dr. Nader’s discretion). The patient is then given radiation in conjunction with Calypso.
Patients with stage I, II and III primary or metastatic lung cancers may be potential candidates for this clinical trial. The trial seeks to determine if using Calypso for the lung will allow
the system to track movement and deliver radiation in conjunction with the movement of the breathing lungs. All patients at CTCA are screened for the eligibility to participate in any of our
open clinical trials.
“I am always a proponent for any technology which may help us in our fight against cancer,” added Dr. Nader.
According to the American Cancer Society about 221,000 new cases of lung cancer are expected to be diagnosed this year in the United States. The average lifetime chance that a
man will develop lung cancer is about one in 13. For a woman it is one in 16. These numbers include both smokers and non-smokers. For smokers the risk is much higher, while for non-
smokers the risk is lower.
About Cancer Treatment Centers of America®
Cancer Treatment Centers of America Global, Inc. (CTCA), headquartered in Boca Raton, Fla., is a national network of five hospitals that serves adult patients who are fighting cancer. CTCA® offers an integrative approach to care that combines advancements in genomic testing and precision cancer treatment, surgery, radiation, immunotherapy and chemotherapy, with evidence-informed supportive therapies designed to help patients physically and emotionally by enhancing their quality of life while managing side effects both during and after treatment. CTCA serves patients from around the world at its hospitals in Atlanta, Chicago, Philadelphia, Phoenix and Tulsa. Reflecting our patient-centered approach to cancer care, our patient satisfaction scores consistently rank among the highest in the country for cancer care providers, and CTCA is also rated one of the most admired hospital systems in the country in national consumer surveys. For more information, visit cancercenter.com, Facebook.com/cancercenter and Twitter.com/cancercenter.